Miltefosine
- Product Name
- Miltefosine
- CAS No.
- 58066-85-6
- Chemical Name
- Miltefosine
- Synonyms
- HPC;C16:0;mil;HEPC;IMpavido;Miltefosin;HEXADECYLPHOSPHOCHOLINE;d18506;Miltex;C16 : O
- CBNumber
- CB6370752
- Molecular Formula
- C21H46NO4P
- Formula Weight
- 407.57
- MOL File
- 58066-85-6.mol
Miltefosine Property
- Melting point:
- 232-234° (dec)
- storage temp.
- room temp
- solubility
- H2O: soluble10mg/mL, clear, colorless
- form
- Crystalline solid
- color
- White to Almost white
- InChI
- InChI=1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3
- InChIKey
- PQLXHQMOHUQAKB-UHFFFAOYSA-N
- SMILES
- O(CCCCCCCCCCCCCCCC)P([O-])(=O)OCC[N+](C)(C)C
- CAS DataBase Reference
- 58066-85-6(CAS DataBase Reference)
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Danger
- Hazard statements
-
H301Toxic if swalloed
- Precautionary statements
-
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P270Do not eat, drink or smoke when using this product.
P301+P310IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P405Store locked up.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- M5571
- Product name
- Miltefosine
- Purity
- zwitterionic
- Packaging
- 50mg
- Price
- $112
- Updated
- 2024/03/01
- Product number
- 475841
- Product name
- Miltefosine
- Packaging
- 50mg
- Price
- $101
- Updated
- 2022/05/15
- Product number
- M2445
- Product name
- Miltefosine
- Purity
- >98.0%(HPLC)(T)
- Packaging
- 100mg
- Price
- $60
- Updated
- 2024/03/01
- Product number
- M2445
- Product name
- Miltefosine
- Purity
- >98.0%(HPLC)(T)
- Packaging
- 1g
- Price
- $238
- Updated
- 2024/03/01
- Product number
- 63280
- Product name
- Miltefosine
- Purity
- ≥98%
- Packaging
- 50mg
- Price
- $32
- Updated
- 2024/03/01
Miltefosine Chemical Properties,Usage,Production
Description
Miltefosin, representing the prototype of a new phospholipid structure, was introduced for the palliative treatment of skin metastases in patients with breast cancer. It is highly active against the human leukemia tumor cells xenograft in nude mice, leading to growth inhibition and regression of large established tumors. Its mode of antitumor activity is not mediated by the host immune system but by its pharmacological effects at the level of the cancer cell membrane, distinctly different from that of the classical cytostatic drugs which interact with cell proliferation at the level of DNA replication. Protein kinase C inhibition has been suggested as a possible mechanism.
Originator
Asta Medica (Germany)
Uses
A phospholipid drug with antineoplastic and antiprotozoal/antifungal properties, also acts as an Akt inhibitor, and under investigation as a potential therapy against HIV infection.
Definition
ChEBI: A phospholipid that is the hexadecyl monoester of phosphocholine.
brand name
Miltex
Antimicrobial activity
Concentrations of 1–5 μm inhibit the promastigotes and amastigotes of Leishmania spp. and the epimastigotes and amastigotes of T. cruzi. Inhibitory concentrations against T. brucei spp. and E. histolytica are closer to 50 μm. Acanthamoeba spp. are variably susceptible, depending on the experimental conditions.
Acquired resistance
There are no reports of clinical resistance in Leishmania so far. Experimental resistance has been induced in vitro against the promastigote stage of Leishmania and two plasma membrane proteins, LdMT and Ld Ros3, are necessary for miltefosine uptake. There is evidence that reduced sensitivity of promastigotes is passed on to intracellular amastigotes.
Pharmaceutical Applications
An alkylphospholipid, originally investigated as an anticancer compound, formulated for oral administration.
Biochem/physiol Actions
Inhibitor of protein kinase C and of phosphatidylcholine synthesis. Used for the treatment of visceral and cutaneous leishmaniasis. Active against metronidazole-resistant and -susceptible strains of Trichomonas vaginalis
Pharmacokinetics
In rodent models the drug is almost completely absorbed after
oral administration. About 90% is bound to plasma proteins. It
is widely distributed in the body; studies in rats showed highest
uptake in kidney, liver and spleen. In rats and dogs bioavailability
was 82% and 94%, with maximum values reached after 4–48 h.
In adult human trials repeated oral dosing with 100 mg per
day achieved a peak plasma concentration of 70 mg/L after
8–24 h (day 23). The half-life is 6–8 days.
Clinical Use
Visceral leishmaniasis
Cutaneous leishmaniasis
Side effects
Mild to moderate gastrointestinal side effects are reported in 40–60% of patients. Moderate to severe nephrotoxicity was seen in 2% and 1% of patients, respectively; increases in creatinine levels were reversible. Miltefosine is contraindicated in pregnancy, based on findings of teratogenicity in rats. It causes hemolysis and cannot be given intravenously.
storage
-20°C
Miltefosine Preparation Products And Raw materials
Raw materials
Preparation Products
Miltefosine Suppliers
- Tel
- --
- Fax
- --
- chemos@chemos.de
- Country
- Germany
- ProdList
- 6727
- Advantage
- 58
- Tel
- --
- Fax
- --
- info@glycon.de
- Country
- Germany
- ProdList
- 36
- Advantage
- 58
- Tel
- --
- Fax
- --
- sales@chemos-group.com
- Country
- Germany
- ProdList
- 6350
- Advantage
- 71
View Lastest Price from Miltefosine manufacturers
- Product
- Miltefosine 58066-85-6
- Price
- US $0.00/KG
- Min. Order
- 1KG
- Purity
- 98%min
- Supply Ability
- 30tons/month
- Release date
- 2023-01-10
- Product
- miltefosine;hexadecylphosphocholine 58066-85-6
- Price
- US $9000.00/Kg/Drum
- Min. Order
- 1KG
- Purity
- 98.5%
- Supply Ability
- 1000tons/month
- Release date
- 2020-07-13
- Product
- Miltefosine 58066-85-6
- Price
- US $0.00/g
- Min. Order
- 1g
- Purity
- More Than 99%
- Supply Ability
- 100kg/Month
- Release date
- 2024-09-12